Arrowstreet Capital’s Champions Oncology CSBR Stock Holding History

Arrowstreet Capital’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-22,865	Closed	-$179K	–	1561
2019 Q2	$179K	Hold	22,865	–	–	﹤0.01%	1315
2019 Q1	$224K	Hold	22,865	–	–	﹤0.01%	1621
2018 Q4	$179K	Buy	22,865 +9,959	+77%	+$114K	﹤0.01%	1267
2018 Q3	$225K	Buy	+12,906	New	+$115K	﹤0.01%	1011

Other funds holding CSBR

BPI

Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Arrowstreet Capital's CSBR Position: Q3 2019 in Review

Arrowstreet Capital sold out of Champions Oncology (CSBR) in Q3 2019, closing a stake of 22,865 shares — an estimated $179K sold.

Arrowstreet Capital first reported a position in CSBR in Q3 2018 and held it in 4 quarters. The position peaked at $225K in Q3 2018. 33 funds tracked by Wall St. Rank hold CSBR as of Q3 2019.

Arrowstreet Capital reported no remaining Champions Oncology position as of Q3 2019 after selling out during the quarter.
Arrowstreet Capital sold 22,865 Champions Oncology shares in Q3 2019, an estimated $179K.
Arrowstreet Capital first reported a position in Champions Oncology in Q3 2018 and held it in 4 quarters.
Arrowstreet Capital's Champions Oncology position peaked at $225K in Q3 2018.
33 funds tracked by Wall St. Rank held Champions Oncology as of Q3 2019.

Based on Arrowstreet Capital's 13F filing for Q3 2019, filed 14 Nov 2019.